Volta Medical reveals results of first AI-assisted cardiac ablation trial

Volta Medical presented results from the transatlantic randomized TAILORED-AF trial, comparing AI-assisted cardiac ablation to conventional treatment for persistent atrial fibrillation. This trial demonstrates the superiority of personalized ablation based on AI in terms of absence of recurrence of atrial fibrillation at 12 months.

The results, revealed by Prof. Isabel Deisenhofer at the “Heart Rhythm 2024” program, show that 88% of patients in the IA group were free of AF at 12 months, compared to 70% in the conventional group. Additionally, 66% of patients in the IA group experienced acute AF cessation, compared to 15% in the conventional group.

187 patients were treated with AI-assisted ablation in addition to pulmonary vein isolation (PVI), and 183 with PVI alone. The trial, including 51 cardiologists from 26 centers, demonstrates superior results for personalized AI-guided ablation, particularly for patients with persistent AF for more than six months.